JPMorgan analyst Jessica Fye downgraded Halozyme Therapeutics (NASDAQ: HALO) from Overweight to Neutral with a price target of $57.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE